EBRD invests in the rapidly growing Turkish tech company, obilet.com
12.12.2019 14:02:00 EET | Business Wire | Press release
European Bank for Reconstruction and Development (EBRD) invested in obilet.com, the online sales platform for users to purchase bus and airline tickets. EBRD, which offers financing for thousands of projects to support local growth in European countries, has invested $11 billion in Turkish businesses and projects to date. Earlybird Venture Capital, an investor in obilet.com, announced that it will also participate in the next round of funding.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191212005302/en/
EBRD added obilet.com, Turkey's fastest-growing online ticket sales platform, to its investment portfolio. Yigit Gurocak, (obilet.com CEO and Co-founder) and Ali Yılmaz, (obilet.com Co-founder) (Photo: Business Wire)
Yigit Gurocak, CEO - obilet.com, said that the company aimed to provide services to different segments of the transportation industry by expanding its teams in 2020 with the support of new investments.
The company, currently at 400 million visitors, aims to sell 18 million tickets in 2020!
obilet.com, which offers comparison and purchasing options for bus and airline tickets of more than 150 bus operators and 1000 airlines, was founded in 2012 by two university students and entrepreneurs, Ali Yilmaz and Yigit Gurocak. The company’s CEO Yigit Gurocak summarized the last seven years, “Starting from its inception to the present day, obilet.com recorded outstanding growth to reach 400 million visitors, now ranks the top-visited travel site in Turkey.”
The initiative of two entrepreneurs’ dreams, obilet.com currently operates with 160 employees and is expected to maintain its growth in the Turkish travel industry, which reportedly has a size of approximately $15 billion. Yigit Gurocak said that the company aims to sell 18 million tickets in 2020 on obilet.com and the mobile app in Turkey, where 300 million tickets are sold in total.
The Turkish startup to receive highest international funding
According to Startups Watch data, obilet.com stood out as the Turkish startup to receive the highest amount of international funding in 2018 Q2 and when the investment was acquired in November 2019, it was the largest amount of investment of 2019 up until that point. With the participation of EBRD in the latest round, obilet.com has received its fourth investment round in the last five years leading the Turkish technology and travel sectors in this aspect. With this investment, obilet.com raised $10 million within one year.
Named “Europe's Best Travel App” by Mastercard in 2015, obilet.com ranked eighth among the fastest-growing companies listed in the 2017 Deloitte Technology Fast 50 program with a growth rate of 1041%. Most recently, obilet.com was also listed among Turkey’s 100 Fastest Growing Businesses according to the results of a 2019 survey conducted by the Union of Chambers and Commodity Exchanges of Turkey (TOBB) and the Economic Policy Research Foundation of Turkey (TEPAV).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191212005302/en/
Contact information
Contact Details:
Sena Ozkurt
sena@obilet.com
+905348960414
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HUI (HUI:VSE) Merges Traditional and Crypto Finance: Commences Continuous Trading in Vienna With Leading Market Maker and Announces Impending Token Listing on Major Global Exchange15.6.2026 12:15:00 EEST | Press release
HUI S.p.A., the pioneering vertical SuperApp and SaaS company dedicated to the global Venture Capital and startup ecosystem listed on the Vienna Stock Exchange, today released its global product strategy, marking an unprecedented convergence between traditional regulated markets and decentralized finance. Driven by a +15% stock surge and the consolidation of its $25 million round a equity commitment fully subscribed by global institutional fund Nimbus Capital, the company announced its upcoming transition to continuous trading on the Vienna market in partnership with a leading European market maker, alongside the activation of the initial PUT options tied to the round. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612936893/en/ HUI (HUI:VSE) merges traditional and crypto finance: commences continuous trading in Vienna with leading market maker and announces impending token listing on major global exchange Emmanuelle Deba
Syngenta Signs MoU to Be Strategic Partner in India’s First Open-Data Agricultural Ecosystem Annam.AI15.6.2026 10:35:00 EEST | Press release
India’s agriculture sector is a global powerhouse, uniquely characterized by its massive scale, vast arable land, diverse agro-climatic zones and rich biodiversity. These strengths have propelled the country to become one of the world’s leading producers of crops such as rice and wheat. However, farmers in the country face significant challenges – from erratic monsoons, severe droughts and unseasonal rains compounded by El Nino, to pests and diseases that destroy an estimated 30 percent of crops annually. More than 80 percent of India’s estimated 150 million farming households are composed of smallholder farmers who operate on less than two hectares of land. This limits economies of scale, sets obstacles to the wider adoption of advanced technologies and could widen a systemic gap between large commercial agricultural operations and the bulk of its farming population. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202606151544
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 10:00:00 EEST | Press release
Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discovery teams to accelerate decision-making, streamline workflows, and advance programs more efficiently from hit identification through lead optimization. "Drug discovery increasingly requires seamless integration between chemistry and biology," said Michael Dabrowski, Chief Executive Officer of Pelago Bioscience. "By bringing RG Discovery
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera
Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom